144 related articles for article (PubMed ID: 37995412)
1. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors.
Mertens RB; Makhoul EP; Li X; Dadmanesh F
Ann Diagn Pathol; 2024 Feb; 68():152226. PubMed ID: 37995412
[TBL] [Abstract][Full Text] [Related]
2. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus.
Hoppe S; Meder L; Gebauer F; Ullrich RT; Zander T; Hillmer AM; Buettner R; Plum P; Puppe J; Malter W; Quaas A
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230712
[TBL] [Abstract][Full Text] [Related]
3. Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors.
Dum D; Taherpour N; Menz A; Höflmayer D; Völkel C; Hinsch A; Gorbokon N; Lennartz M; Hube-Magg C; Fraune C; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Krech T; Luebke AM
Pathobiology; 2022; 89(4):245-258. PubMed ID: 35477165
[TBL] [Abstract][Full Text] [Related]
4. TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer.
Cortesi M; Zanoni M; Maltoni R; Ravaioli S; Tumedei MM; Pirini F; Bravaccini S
Expert Opin Ther Targets; 2022 Jul; 26(7):593-602. PubMed ID: 35962580
[TBL] [Abstract][Full Text] [Related]
5. Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer.
Vidula N; Yau C; Rugo H
Breast Cancer Res Treat; 2022 Aug; 194(3):569-575. PubMed ID: 35789445
[TBL] [Abstract][Full Text] [Related]
6. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
Jeon Y; Jo U; Hong J; Gong G; Lee HJ
BMC Cancer; 2022 Sep; 22(1):1014. PubMed ID: 36153494
[TBL] [Abstract][Full Text] [Related]
7. TROP2 Expression in Sebaceous and Sweat Gland Carcinoma.
Ito T; Hashimoto H; Tanaka Y; Tanegashima K; Murata M; Ichiki T; Iwasaki T; Oda Y; Kaku-Ito Y
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160059
[TBL] [Abstract][Full Text] [Related]
8. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
9. Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities.
Spring LM; Nakajima E; Hutchinson J; Viscosi E; Blouin G; Weekes C; Rugo H; Moy B; Bardia A
Oncologist; 2021 Oct; 26(10):827-834. PubMed ID: 34176192
[TBL] [Abstract][Full Text] [Related]
10. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Furlanetto J; Marmé F; Loibl S
Future Oncol; 2022 Sep; 18(28):3199-3215. PubMed ID: 36069628
[TBL] [Abstract][Full Text] [Related]
11. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
[TBL] [Abstract][Full Text] [Related]
12. TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy.
Hegedüs L; Okumus Ö; Mairinger F; Ploenes T; Reuter S; Schuler M; Welt A; Vega-Rubin-de-Celis S; Theegarten D; Bankfalvi A; Aigner C; Hegedüs B
Lung Cancer; 2023 Apr; 178():237-246. PubMed ID: 36907051
[TBL] [Abstract][Full Text] [Related]
13. TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas.
Chartier S; Brochard C; Martinat C; Coussy F; Feron JG; Kirova Y; Cottu P; Marchiò C; Vincent-Salomon A
Histopathology; 2023 Apr; 82(5):664-671. PubMed ID: 36527253
[TBL] [Abstract][Full Text] [Related]
14. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A; Hurvitz SA; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Sardesai SD; Kalinsky K; Zelnak AB; Weaver R; Traina T; Dalenc F; Aftimos P; Lynce F; Diab S; Cortés J; O'Shaughnessy J; Diéras V; Ferrario C; Schmid P; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo MS; Itri LM; Rugo HS;
N Engl J Med; 2021 Apr; 384(16):1529-1541. PubMed ID: 33882206
[TBL] [Abstract][Full Text] [Related]
15. A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Spears PA; Tolaney SM
Future Oncol; 2024 Apr; 20(11):635-651. PubMed ID: 38270051
[TBL] [Abstract][Full Text] [Related]
16. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
17. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
[TBL] [Abstract][Full Text] [Related]
18. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS; Bardia A; Marmé F; Cortés J; Schmid P; Loirat D; Trédan O; Ciruelos E; Dalenc F; Gómez Pardo P; Jhaveri KL; Delaney R; Valdez T; Wang H; Motwani M; Yoon OK; Verret W; Tolaney SM
Lancet; 2023 Oct; 402(10411):1423-1433. PubMed ID: 37633306
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
Satti SA; Sheikh MS
Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
[TBL] [Abstract][Full Text] [Related]
20. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer.
Liu X; Deng J; Yuan Y; Chen W; Sun W; Wang Y; Huang H; Liang B; Ming T; Wen J; Huang B; Xing D
Pharmacol Ther; 2022 Nov; 239():108296. PubMed ID: 36208791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
